Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy.
Arrhythmogenic cardiomyopathy
Arrhythmogenic genotype
Dilated cardiomyopathy
Dilated cardiomyopathy with arrhythmic phenotype
Non-sustained ventricular tachycardia
Unexplained syncope
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
revised:
22
12
2023
received:
15
07
2023
accepted:
05
02
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
aheadofprint
Résumé
Dilated cardiomyopathy (DCM) with arrhythmic phenotype combines phenotypical aspects of DCM and predisposition to ventricular arrhythmias, typical of arrhythmogenic cardiomyopathy. The definition of DCM with arrhythmic phenotype is not universally accepted, leading to uncertainty in the identification of high-risk patients. This study aimed to assess the prognostic impact of arrhythmic phenotype in risk stratification and the correlation of arrhythmic markers with high-risk arrhythmogenic gene variants in DCM patients. In this multicentre study, DCM patients with available genetic testing were analysed. The following arrhythmic markers, present at baseline or within 1 year of enrolment, were tested: unexplained syncope, rapid non-sustained ventricular tachycardia (NSVT), ≥1000 premature ventricular contractions/24 h or ≥50 ventricular couplets/24 h. LMNA, FLNC, RBM20, and desmosomal pathogenic or likely pathogenic gene variants were considered high-risk arrhythmogenic genes. The study endpoint was a composite of sudden cardiac death and major ventricular arrhythmias (SCD/MVA). We studied 742 DCM patients (45 ± 14 years, 34% female, 410 [55%] with left ventricular ejection fraction [LVEF] <35%). During a median follow-up of 6 years (interquartile range 1.6-12.1), unexplained syncope and NSVT were the only arrhythmic markers associated with SCD/MVA, and the combination of the two markers carried a significant additive risk of SCD/MVA, incremental to LVEF and New York Heart Association class. The probability of identifying an arrhythmogenic genotype rose from 8% to 30% if both early syncope and NSVT were present. In DCM patients, the combination of early detected NSVT and unexplained syncope increases the risk of life-threatening arrhythmic outcomes and can aid the identification of carriers of malignant arrhythmogenic genotypes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Society of Cardiology.
Références
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-1816. https://doi.org/10.1161/CIRCULATIONAHA.106.174287
Merlo M, Cannatà A, Pio Loco C, Stolfo D, Barbati G, Artico J, et al. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2020;22:1111-1121. https://doi.org/10.1002/ejhf.1914
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126. https://doi.org/10.1093/eurheartj/ehac262
Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, et al.; Familial Cardiomyopathy Registry. Arrhythmogenic phenotype in dilated cardiomyopathy: Natural history and predictors of life-threatening arrhythmias. J Am Heart Assoc 2015;4:e002149. https://doi.org/10.1161/JAHA.115.002149
Zegkos T, Panagiotidis T, Parcharidou D, Efthimiadis G. Emerging concepts in arrhythmogenic dilated cardiomyopathy. Heart Fail Rev 2021;26:1219-1229. https://doi.org/10.1007/s10741-020-09933-z
Lukas Laws J, Lancaster MC, Ben Shoemaker M, Stevenson WG, Hung RR, Wells Q, et al. Arrhythmias as presentation of genetic cardiomyopathy. Circ Res 2022;130:1698-1722. https://doi.org/10.1161/CIRCRESAHA.122.319835
Paldino A, Dal Ferro M, Stolfo D, Gandin I, Medo K, Graw S, et al. Prognostic prediction of genotype vs phenotype in genetic cardiomyopathies. J Am Coll Cardiol 2022;80:1981-1994. https://doi.org/10.1016/j.jacc.2022.08.804
van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers a European cohort study. J Am Coll Cardiol 2012;59:493-500. https://doi.org/10.1016/j.jacc.2011.08.078
Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440-2451. https://doi.org/10.1016/j.jacc.2016.09.927
De Angelis G, Merlo M, Barbati G, Bertolo S, De Luca A, Ramani F, et al. Longitudinal arrhythmic risk assessment based on ejection fraction in patients with recent-onset nonischemic dilated cardiomyopathy. J Am Soc Echocardiogr 2022;35:801-809.e803. https://doi.org/10.1016/j.echo.2022.03.019
Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2019;74:1480-1490. https://doi.org/10.1016/j.jacc.2019.06.072
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al.; ESC Scientific Document Group. ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;2023:3503-3626. https://doi.org/10.1093/eurheartj/ehad194
Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: Changing mortality over the last 30 years. Eur J Heart Fail 2014;16:317-324. https://doi.org/10.1002/ejhf.16
Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria. Circulation 2010;121:1533-1541. https://doi.org/10.1161/CIRCULATIONAHA.108.840827
Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, et al. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J Card Fail 2018;24:281-302. https://doi.org/10.1016/j.cardfail.2018.03.004
Richards S, Aziz N, Bale S, Bick D, das S, Gastier-Foster J, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424. https://doi.org/10.1038/gim.2015.30
James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. Circ Genom Precis Med 2021;14:e003273. https://doi.org/10.1161/CIRCGEN.120.003273
Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation 2021;144:7-19. https://doi.org/10.1161/CIRCULATIONAHA.120.053033
Lyu J, Hou Y, Chen Z. The use of restricted mean time lost under competing risks data. BMC Med Res Methodol 2020;20:197. https://doi.org/10.1186/s12874-020-01040-9
Perego C, Sbolli M, Specchia C, Fiuzat M, McCaw ZR, Metra M, et al. Utility of restricted mean survival time analysis for heart failure clinical trial evaluation and interpretation. JACC Heart Fail 2020;8:973-983. https://doi.org/10.1016/j.jchf.2020.07.005
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al.; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221-1230. https://doi.org/10.1056/NEJMoa1608029
Ataklte F, Erqou S, Laukkanen J, Kaptoge S. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. Am J Cardiol 2013;112:1263-1270. https://doi.org/10.1016/j.amjcard.2013.05.065
Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular complex-induced cardiomyopathy: A potentially reversible cause of heart failure. J Cardiovasc Electrophysiol 2000;11:328-329. https://doi.org/10.1111/j.1540-8167.2000.tb01802.x
Muser D, Nucifora G, Pieroni M, Castro SA, Casado Arroyo R, Maeda S, et al. Prognostic value of nonischemic ringlike left ventricular scar in patients with apparently idiopathic nonsustained ventricular arrhythmias. Circulation 2021;143:1359-1373. https://doi.org/10.1161/CIRCULATIONAHA.120.047640
Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: Prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985;55:146-151. https://doi.org/10.1016/0002-9149(85)90317-0
Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA investigators. Circulation 1996;94:3198-3203. https://doi.org/10.1161/01.cir.94.12.3198
Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119:1703-1710. https://doi.org/10.1161/CIRCULATIONAHA.108.798314
Cannatà A, Fabris E, Merlo M, Artico J, Gentile P, Pio Loco C, et al. Sex differences in the long-term prognosis of dilated cardiomyopathy. Can J Cardiol 2020;36:37-44. https://doi.org/10.1016/j.cjca.2019.05.031
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the. Circ Heart Fail 2020;13:e006832. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006832